Phase 3 RCT of 1,016 patients with relapsing MS: intramuscular GA Depot 40 mg every 4 weeks vs placebo lowered annualised relapse rate (0.18 vs 0.26; 30.1% relative reduction) and contrast-enhancing lesions; injection site reactions 46.1% vs 28.7%.
RCTn = 1,016
Miller et al. GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial